Inventor · disambiguated record
Atsuhiko Maeda
Also filed as: MAEDA ATSUHIKO
26 granted patents·43 pending applications·585 citations·filing 2008–2025
97Inventor score
Top patents by PatentIndex Score
69 records- 0198US10253091B2Antibody constant region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Apr 9, 2019·27 cites·35 claims
- 0298US8562991B2Antibody molecules that bind to IL-6 receptorIGAWA TOMOYUKI·Filed 2009·Granted Oct 22, 2013·130 cites·19 claims
- 0397US11371039B2Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Jun 28, 2022·4 cites·30 claims
- 0497US11359194B2Antigen-binding molecule capable of binding two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Jun 14, 2022·4 cites·29 claims
- 0597US10472623B2Antigen-binding molecule capable of binding two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Nov 12, 2019·29 cites·21 claims
- 0697US10066018B2Antibody constant region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Sep 4, 2018·28 cites·47 claims
- 0797US9890377B2Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Feb 13, 2018·34 cites·24 claims
- 0897US9228017B2Antibody constant region variantIGAWA TOMOYUKI·Filed 2010·Granted Jan 5, 2016·44 cites·12 claims
- 0996US11718678B2Method for altering plasma retention and immunogenicity of antigen-binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Granted Aug 8, 2023·7 cites·16 claims
- 1096US10662245B2Methods of reducing IL-6 activity for disease treatmentCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Granted May 26, 2020·22 cites·25 claims
- 1196US10253100B2Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearanceCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Apr 9, 2019·37 cites·36 claims
- 1296US9868948B2Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Jan 16, 2018·27 cites·34 claims
- 1395US9969800B2IL-8 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Granted May 15, 2018·37 cites·36 claims
- 1494US10618965B2Method for altering plasma retention and immunogenicity of antigen-binding moleculeIGAWA TOMOYUKI·Filed 2012·Granted Apr 14, 2020·32 cites·33 claims
- 1594US10519229B2Nucleic acids encoding IL-8 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Dec 31, 2019·22 cites·33 claims
- 1693US11827699B2Methods for producing antibodies promoting disappearance of antigens having plurality of biological activitiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Nov 28, 2023·8 cites·20 claims
- 1793US11180548B2Methods of neutralizing IL-8 biological activityCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Nov 23, 2021·6 cites·11 claims
- 1893US2025101118A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 1992US10435458B2Antibody constant region variants with reduced Fcgammar bindingKURAMOCHI TAICHI·Filed 2011·Granted Oct 8, 2019·23 cites·2 claims
- 2092US2025346677A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 2191US11891434B2Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Feb 6, 2024·6 cites·32 claims
- 2291US2024301075A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 2389US9340615B2Anti-AXL antibodyMAEDA ATSUHIKO·Filed 2010·Granted May 17, 2016·23 cites·23 claims
- 2488US10150808B2Modified antibody constant regionsKURAMOCHI TAICHI·Filed 2010·Granted Dec 11, 2018·22 cites·5 claims
- 2588US2024010738A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2686US2024002836A1Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2786US2023159648A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2885US10556949B2Antigen-binding molecule inducing immune response to target antigenCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Feb 11, 2020·8 cites·26 claims
- 2983US2024279325A1Antigen-binding molecule promoting disappearance of antigens having plurality of biological activitiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3083US2022306755A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3182US2023220083A1Antibodies with modified affinity to fcrn that promote antigen clearanceCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 3280US2022041741A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3380US2024117059A1THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCECHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3479US9556264B2Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredientCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Jan 31, 2017·5 cites·25 claims
- 3578US2024158482A1Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 3675US2022064264A1Antibody constant region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3774US2020231688A1Antibody moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 3873US2022389118A1Antigen-binding molecule for promoting elimination of antigensCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 3973US2021206862A1Anti-il-6 receptor antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 4070US2020048627A1Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 4169US2011111406A1Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2009·Application pending·0 cites
- 4268US2023140797A1ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA Fc GAMMA RIIBCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 4367US2019211081A1Antibody constant region variantCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 4466US2011245473A1Anti-IL-6 Receptor AntibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2008·Application pending·0 cites
- 4566US2017002080A1Antibodies With Modified Affinity To FcRn That Promote Antigen ClearanceCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
- 4664US2017226206A1Antibodies With Modified Affinity To FcRn That Promote Antigen ClearanceCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Application pending·0 cites
- 4763US2017002066A1Antibodies With Modified Affinity To FcRn That Promote Antigen ClearanceCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Application pending·0 cites
- 4863US2013011866A1Antigen-binding molecule capable of binding to two or more antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Application pending·0 cites
- 4963US2019085085A1Anti-il-6 receptor antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Application pending·0 cites
- 5063US2012253016A1Antibody molecules that bind to il-6 receptorIGAWA TOMOYUKI·Filed 2012·Application pending·0 cites
Showing the top 50 of 69 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Atsuhiko Maeda files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →